July 08, 2024
Tirzepatide-treated participants were 3 times more likely than those treated with semaglutide to reach weight loss of 15% or greater, the head-to-head study found.
July 03, 2024
The preserved bone mass observed in participants taking liraglutide and exercising was seen despite weight reduction levels similar to outcomes with semaglutide and tirzepatide.
July 02, 2024
Donanemab, now 1 of 2 antiamyloid medications available, is unique based on evidence that it can be used in limited duration treatment, based on removal of plaque.
July 02, 2024
The international statement targets primary care clinicians and endocrinologists with detailed guidance on monitoring disease progression and providing education.
July 01, 2024
The novel vaccination is recommended as an option for adults aged 65 years and older who have not received a pneumococcal conjugate vaccine.
July 01, 2024
Neurocrine Biosciences made the announcement and said, if approved in December, crinecerfont will be the first new treatment and treatment approach to CAH in 70 years.
July 01, 2024
The standard of care for congenital adrenal hyperplasia has not changed in more than 60 years nor have the challenges it presents been overcome.
July 01, 2024
Investigational treatments for congenital adrenal hyperplasia are focused on new ways to manage symptoms without the need for supraphysiologic doses of glucocorticoids.
July 01, 2024
Current therapies fall short of quelling the long-term exposure to and adverse effects of excessive androgen levels experienced by adults with CAH.
June 27, 2024
The committee endorsed a universal recommendation for a single lifetime dose of RSV vaccine for adults aged ≥75 years and a risk-based recommendation for those aged 60 to 74 years.